Nova Patents
AT522545T

Amidated glargine insulin

Abstract

The Invention relates to a modified by amidation insulin glargine, especially Gly (A21), Arg (B31), Arg-amide (B32) human insulin (insulin glargine amide).

Term

0.8 yearsleft in the term

Expires 5 July 2027.

  1. Priority
  2. Filed
  3. Granted
  4. Today
  5. Expires

12 members in 8 offices

This recordMember, by publication datePriority claim

Priority claims2

Priority claims
DocumentOfficeKindDate
102006031962GermanyA
2007005932European Patent Office (EPO)W

Members12

Family members, oldest first
DocumentOfficeKind
DE102006031962A1GermanyA1
WO2008006496A1World Intellectual Property Organization (WIPO)A1
TW200817432ATaiwan Province of ChinaA
AR061866A1ArgentinaA1
EP2041169A1European Patent Office (EPO)A1
US2009176692A1United States of AmericaA1
JP2009542741AJapanA
EP2041169B1European Patent Office (EPO)B1
AT522545TThis recordAustriaT
ATE522545T1AustriaT1
US8048854B2United States of AmericaB2
JP5325778B2JapanB2